Summary
Global Markets Direct’s, ‘Sunovion Pharmaceuticals Inc. - Product Pipeline Review - 2016’, provides an overview of the Sunovion Pharmaceuticals Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Sunovion Pharmaceuticals Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Sunovion Pharmaceuticals Inc.
- The report provides overview of Sunovion Pharmaceuticals Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sunovion Pharmaceuticals Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sunovion Pharmaceuticals Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Sunovion Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sunovion Pharmaceuticals Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sunovion Pharmaceuticals Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Sunovion Pharmaceuticals Inc. Snapshot 6
Sunovion Pharmaceuticals Inc. Overview 6
Key Information 6
Key Facts 6
Sunovion Pharmaceuticals Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Sunovion Pharmaceuticals Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Sunovion Pharmaceuticals Inc. - Pipeline Products Glance 14
Sunovion Pharmaceuticals Inc. - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Sunovion Pharmaceuticals Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Sunovion Pharmaceuticals Inc. - Early Stage Pipeline Products 18
IND/CTA Filed Products/Combination Treatment Modalities 18
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Sunovion Pharmaceuticals Inc. - Drug Profiles 21
eslicarbazepine acetate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
dasotraline 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
glycopyrrolate 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
DSP-2230 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
DSP-3748 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SEP-363856 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SEP-360 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SEP-39 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule 1 for Neuropsychiatric Disorders 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule for Neuropsychiatric Disorders 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
EP-103 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules for Central Nervous System Disorders 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Modulate GPCR and Ion Channel for Psychiatric Disorders 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Sunovion Pharmaceuticals Inc. - Pipeline Analysis 39
Sunovion Pharmaceuticals Inc. - Pipeline Products by Target 39
Sunovion Pharmaceuticals Inc. - Pipeline Products by Route of Administration 41
Sunovion Pharmaceuticals Inc. - Pipeline Products by Molecule Type 42
Sunovion Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action 43
Sunovion Pharmaceuticals Inc. - Recent Pipeline Updates 45
Sunovion Pharmaceuticals Inc. - Dormant Projects 51
Sunovion Pharmaceuticals Inc. - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
dasotraline 52
DSP-1053 52
DSP-8658 52
SEP-228432 52
tecastemizole 52
Sunovion Pharmaceuticals Inc. - Locations and Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
List of Tables
Sunovion Pharmaceuticals Inc., Key Information 6
Sunovion Pharmaceuticals Inc., Key Facts 6
Sunovion Pharmaceuticals Inc. - Pipeline by Indication, 2016 8
Sunovion Pharmaceuticals Inc. - Pipeline by Stage of Development, 2016 10
Sunovion Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2016 11
Sunovion Pharmaceuticals Inc. - Partnered Products in Pipeline, 2016 12
Sunovion Pharmaceuticals Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13
Sunovion Pharmaceuticals Inc. - Pre-Registration, 2016 14
Sunovion Pharmaceuticals Inc. - Phase III, 2016 15
Sunovion Pharmaceuticals Inc. - Phase II, 2016 16
Sunovion Pharmaceuticals Inc. - Phase I, 2016 17
Sunovion Pharmaceuticals Inc. - IND/CTA Filed, 2016 18
Sunovion Pharmaceuticals Inc. - Preclinical, 2016 19
Sunovion Pharmaceuticals Inc. - Discovery, 2016 20
Sunovion Pharmaceuticals Inc. - Pipeline by Target, 2016 39
Sunovion Pharmaceuticals Inc. - Pipeline by Route of Administration, 2016 41
Sunovion Pharmaceuticals Inc. - Pipeline by Molecule Type, 2016 42
Sunovion Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2016 43
Sunovion Pharmaceuticals Inc. - Recent Pipeline Updates, 2016 45
Sunovion Pharmaceuticals Inc. - Dormant Developmental Projects,2016 51
Sunovion Pharmaceuticals Inc. - Discontinued Pipeline Products, 2016 52
Sunovion Pharmaceuticals Inc., Other Locations 53
Sunovion Pharmaceuticals Inc., Subsidiaries 53
List of Figures
Sunovion Pharmaceuticals Inc. - Pipeline by Top 10 Indication, 2016 8
Sunovion Pharmaceuticals Inc. - Pipeline by Stage of Development, 2016 10
Sunovion Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2016 11
Sunovion Pharmaceuticals Inc. - Partnered Products in Pipeline, 2016 12
Sunovion Pharmaceuticals Inc. - Pipeline by Top 10 Target, 2016 39
Sunovion Pharmaceuticals Inc. - Pipeline by Route of Administration, 2016 41
Sunovion Pharmaceuticals Inc. - Pipeline by Molecule Type, 2016 42
Sunovion Pharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 43
